Mycosis fungoides medical therapy: Difference between revisions
Jump to navigation
Jump to search
Line 16: | Line 16: | ||
* '''Stage IB-IIA''' | * '''Stage IB-IIA''' | ||
** Generalized skin directed therapy with or without combination other skin directed therapies<ref name="pmid9923777">{{cite journal |vauthors=Kim YH, Chow S, Varghese A, Hoppe RT |title=Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides |journal=Arch Dermatol |volume=135 |issue=1 |pages=26–32 |date=January 1999 |pmid=9923777 |doi= |url=}}</ref> | ** Generalized skin directed therapy with or without combination other skin directed therapies<ref name="pmid9923777">{{cite journal |vauthors=Kim YH, Chow S, Varghese A, Hoppe RT |title=Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides |journal=Arch Dermatol |volume=135 |issue=1 |pages=26–32 |date=January 1999 |pmid=9923777 |doi= |url=}}</ref> | ||
*** | ***In majority of patients in this stages, skin direct therapy recommended use more than systemic therapy. | ||
*The predominant therapy for cutaneous T cell lymphoma is PUVA. Adjunctive chemotherapy, radiotherapy, biological therapy, retinoid therapy, and photophoresis may be required.<ref name="canadiancancer" /> | *The predominant therapy for cutaneous T cell lymphoma is PUVA. Adjunctive chemotherapy, radiotherapy, biological therapy, retinoid therapy, and photophoresis may be required.<ref name="canadiancancer" /> | ||
Revision as of 17:23, 14 December 2018
Cutaneous T cell lymphoma Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
The predominant therapy for cutaneous T cell lymphoma is PUVA. Adjunctive chemotherapy, radiotherapy, biological therapy, retinoid therapy, and photophoresis may be required.[1]
Medical Therapy
- Patients with Mycosis fungoides are treated based on the stage and the previous treatment history.[2]
Mycosis fungoides
- Stage IA
- Patients with mycosis fungoides in stage IA ( patches, plaques, may be papules involve <10 % of total skin surface) treat by skin-directed therapy [topical corticosteroids, nitrogen mustard (meclorethamin, NH2)].
- Skin direct therapy is recommended more than systemic therapy (chemotherapy+ skin direct therapy) in this stage.[2]
- Systemic therapies +/- topical therapy are recommended for patients who intolerant of topical treatments
- Stage IB-IIA
- Generalized skin directed therapy with or without combination other skin directed therapies[3]
- In majority of patients in this stages, skin direct therapy recommended use more than systemic therapy.
- Generalized skin directed therapy with or without combination other skin directed therapies[3]
- The predominant therapy for cutaneous T cell lymphoma is PUVA. Adjunctive chemotherapy, radiotherapy, biological therapy, retinoid therapy, and photophoresis may be required.[1]
Stage | PUVA | Topical chemotherapy | Systemic chemotherapy | Radiotherapy | Biological therapy | Retinoid therapy | Photopheresis |
---|---|---|---|---|---|---|---|
Stage I |
|
|
|
|
|
|
--------- |
Stage II |
|
|
|
|
|
|
--------- |
Stage III |
|
|
|
|
|
|
|
Stage IV |
|
|
|
|
|
|
|
Recurrent cutaneous T cell lymphoma |
|
|
|
|
|
--------- | --------- |
Treatment | Description | |
---|---|---|
Phototherapy or Ultraviolet light therapy | ||
PUVA (psoralen and ultraviolet A light therapy) |
| |
Ultraviolet B (UVB) light |
| |
Chemotherapy | ||
Topical chemotherapy |
| |
Systemic chemotherapy |
| |
Radiation therapy | ||
Local external beam radiation therapy |
| |
Total skin electron beam (TSEB) therapy |
| |
Biological therapy | ||
Interferon alfa |
| |
Denileukin diftitox |
| |
Retinoid therapy | ||
Retinoids |
| |
Photopheresis | ||
Photopheresis |
|
- During treatment with systemic retinoids, lipid panel and thyroid function tests should be closely monitored
- Gemfibrozil should be avoided because of the known side effects of the combined therapy; fish oil tablets can be used instead
- Some authors have also documented liver toxicities associated with administration of retinodis, and liver function tests (LFTs) should also be monitored in these patients.
- ↑ 1.0 1.1 1.2 1.3 Cutaneous T cell lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/cutaneous-t-cell-lymphoma/?region=on Accessed on January 19, 2016
- ↑ 2.0 2.1 Al Hothali GI (June 2013). "Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach". Int J Health Sci (Qassim). 7 (2): 220–39. PMC 3883611. PMID 24421750.
- ↑ Kim YH, Chow S, Varghese A, Hoppe RT (January 1999). "Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides". Arch Dermatol. 135 (1): 26–32. PMID 9923777.